PMID- 27766784
OWN - NLM
STAT- MEDLINE
DCOM- 20170317
LR  - 20220321
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 7
IP  - 5
DP  - 2016 Sep
TI  - Retrospective study of adjuvant icotinib in postoperative lung cancer patients 
      harboring epidermal growth factor receptor mutations.
PG  - 543-548
LID - 10.1111/1759-7714.12365 [doi]
AB  - BACKGROUND: Epidermal growth factor receptor (EGFR) mutations occur in about 50% 
      of Asian patients with non-small cell lung cancer (NSCLC). Patients with advanced 
      NSCLC and EGFR mutations derive clinical benefit from treatment with 
      EGFR-tyrosine kinase inhibitors (TKIs). This study assessed the efficacy and 
      safety of adjuvant icotinib without chemotherapy in EGFR-mutated NSCLC patients 
      undergoing resection of stage IB-IIIA. METHODS: Our retrospective study enrolled 
      20 patients treated with icotinib as adjuvant therapy. Survival factors were 
      evaluated by univariate and Cox regression analysis. RESULTS: The median 
      follow-up time was 30 months (range 24-41). At the data cut-off, five patients 
      (25%) had recurrence or metastasis and one patient had died of the disease. The 
      two-year disease-free survival (DFS) rate was 85%. No recurrence occurred in the 
      high-risk stage IB subgroup during the follow-up period. In univariate analysis, 
      the micropapillary pattern had a statistically significant effect on DFS ( P = 
      0.040). Multivariate logistic regression analysis showed that there was no 
      independent predictor. Drug related adverse events (AEs) occurred in nine 
      patients (45.0%). The most common AEs were skin-related events and diarrhea, but 
      were relatively mild. No grade 3 AEs or occurrences of intolerable toxicity were 
      observed. CONCLUSIONS: Icotinib as adjuvant therapy is effective in patients 
      harboring EGFR mutations after complete resection, with an acceptable AE profile. 
      Further trials with larger sample sizes might confirm the efficiency of adjuvant 
      TKI in selected patients.
CI  - (c) 2016 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Yao, Shuyang
AU  - Yao S
AD  - Department of Thoracic Surgery, Xuan Wu Hospital, Capital Medical University, 
      Beijing, China.
FAU - Zhi, Xiuyi
AU  - Zhi X
AD  - Department of Thoracic Surgery, Xuan Wu Hospital, Capital Medical University, 
      Beijing, China.
FAU - Wang, Ruotian
AU  - Wang R
AD  - Department of Thoracic Surgery, Xuan Wu Hospital, Capital Medical University, 
      Beijing, China.
FAU - Qian, Kun
AU  - Qian K
AD  - Department of Thoracic Surgery, Xuan Wu Hospital, Capital Medical University, 
      Beijing, China.
FAU - Hu, Mu
AU  - Hu M
AD  - Department of Thoracic Surgery, Xuan Wu Hospital, Capital Medical University, 
      Beijing, China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Department of Thoracic Surgery, Xuan Wu Hospital, Capital Medical University, 
      Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20160613
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Crown Ethers)
RN  - 0 (Quinazolines)
RN  - 9G6U5L461Q (icotinib)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*administration & dosage/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/surgery
MH  - Chemotherapy, Adjuvant
MH  - Crown Ethers/*administration & dosage/adverse effects
MH  - Disease-Free Survival
MH  - ErbB Receptors/*genetics
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Lung Neoplasms/*drug therapy/genetics/surgery
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Neoplasm Staging
MH  - Quinazolines/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC5130296
OTO - NOTNLM
OT  - Adjuvant therapy
OT  - epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
OT  - non-small cell lung cancer (NSCLC)
EDAT- 2016/10/22 06:00
MHDA- 2017/03/18 06:00
PMCR- 2016/09/01
CRDT- 2016/10/22 06:00
PHST- 2016/03/28 00:00 [received]
PHST- 2016/04/27 00:00 [accepted]
PHST- 2016/10/22 06:00 [pubmed]
PHST- 2017/03/18 06:00 [medline]
PHST- 2016/10/22 06:00 [entrez]
PHST- 2016/09/01 00:00 [pmc-release]
AID - TCA12365 [pii]
AID - 10.1111/1759-7714.12365 [doi]
PST - ppublish
SO  - Thorac Cancer. 2016 Sep;7(5):543-548. doi: 10.1111/1759-7714.12365. Epub 2016 Jun 
      13.